The PODO Trial

Trial to Evaluate PF-06730512 in Adults with FSGS; The PODO Trial

The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio (UPCR)). This study may have two doses in two sequential cohorts. A total of 44 patients with FSGS will participate in this clinical trial and will receive the study treatment for 12 weeks.

Organizational Mission

NephCure Kidney International ® is the only organization committed exclusively to support research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome, improve treatment and find a cure.